The purpose of this study is to establish a prospective, single-center platform research based on clinical subtypes to explore precision neoadjuvant therapy in patients with operable breast cancer who met the indications for neoadjuvant chemotherapy and by the update of basic translational research in the center, especially the refinement of typing, the discovery of new targets and the development of novel targeted drugs, verified the effectiveness of new targeted drugs in neoadjuvant therapy.
Histologically confirmed invasive breast cancer of clinical stage T1-4N1-3M0 or cT2-4N0M0;
Age between18-70 years;
Eastern Cooperative Oncology Group (ECOG) performance status 0-1;
ER, PR and HER2 status were measured by immunohistochemistry (IHC);
Previous cytotoxic chemotherapy, endocrine therapy, biological therapy or radiotherapy for any reason;
Patients with New York Heart Association (NYHA) grade II or above heart disease (including grade II);
Patients with severe systemic infections or other serious diseases;
Patients with known allergy or intolerance to the study drug or its excipients;
63
Treatment groupsSee each treatment group below.
Fudan University
Lead sponsor